Compare RNXT & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RNXT | RPID |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.4M | 84.8M |
| IPO Year | 2021 | 2021 |
| Metric | RNXT | RPID |
|---|---|---|
| Price | $1.15 | $0.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $7.13 | $5.75 |
| AVG Volume (30 Days) | ★ 547.8K | 314.3K |
| Earning Date | 11-12-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | 2.78 |
| EPS | ★ N/A | N/A |
| Revenue | $1,123,000.00 | ★ $33,587,000.00 |
| Revenue This Year | $244.84 | $16.95 |
| Revenue Next Year | $195.26 | $17.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2511.63 | 19.74 |
| 52 Week Low | $0.70 | $0.83 |
| 52 Week High | $2.59 | $4.94 |
| Indicator | RNXT | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 30.58 | 21.87 |
| Support Level | $0.83 | N/A |
| Resistance Level | $1.28 | $2.18 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 4.24 | 8.40 |
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.